In all critical stages in the drug life cycle, BaiPharm can provide specific
recommendations and actionable solutions to clients.
WEBINARS
MORE >
Understanding Regulatory Requirements for Exporting Drugs to Cambodia, Laos, and Myanmar
[ Wednesday, 13th December 2023 ]
Understanding Regulatory Requirements for Exporting Drugs to Indonesia and Vietnam
[ Thursday, 30th November 2023 ]
LATEST NEWS
REGULATION
[Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China
The draft brings encouraging news as it suggests that China may accept the original registration application dossier of overseas drugs, including documents related to chemistry, manufacturing, and controls, non-clinical and clinical studies, if they remain applicable.
Apr 24, 2024
REGULATION
China Consults on Self-Evaluation Report Guidance for Generic Drug Registration
On April 2, 2024, China’s Center for Drug Evaluation (CDE) released the two drafts of Chemical, Manufacturing, and Controls (CMC) Self-evaluation Reports on Class 3 Chemical Drug Registration Applications, one for drug substances, and the other for drug products.
Apr 15, 2024
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | March 2024
Check out the latest pharma regulatory updates in China: 1. NMPA Rolls Out the 78th RLD List; 2. NMPA Grants Six Rx-to-OTC Switches; 3. NMPA Implements Electronic Submission for Import and Export License Applications of Anesthetics and Psychotropics; 4. NMPA Issues Regulation on Exploratory Research on Drug Sampling and Testing...
Apr 12, 2024
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | February 2024
Check out the pharma regulatory updates in February 2024: 1. NMPA Issues the 2023 Drug Evaluation Report 2. NMPA Rolls out the 76th and 77th lists of RLDs 3. NMPA Specifies Administrative Penalties for Drug-related Illegalities 4. China Releases Pharmaceutical Guidelines 5. Chinese Pharmacopoeia Commission Consults on Drafts of Drug Standards
Mar 13, 2024
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | January 2024
A recap of China's pharma regulatory updates in Jan 2024: CDE Conditionally Waives Registration Documents for Overseas Manufactured Drugs, NMPA Outlines Key Considerations for Inspecting Third-party Platforms for Online Drug Sales...
Feb 06, 2024